BioCentury | Oct 27, 2014
Clinical News

Sepranolone: Phase II final data

...the exploratory, double-blind, Swedish Phase II trial in 120 patients with PMDD showing that subcutaneous UC1010...
...and that when only patients that were treated as intended were included in the analysis, UC1010...
...Sweden) owns 38% of Umecrine Mood. Umecrine Co. Group , Umea, Sweden Product: Sepranolone ( UC1010...
BioCentury | Jun 16, 2014
Clinical News

Sepranolone: Preliminary Phase II data

...an exploratory, double-blind, Swedish Phase II trial in 120 patients with PMDD showing that subcutaneous UC1010...
...did show a significant difference between UC1010 and placebo, but did not disclose details (p<0.05). UC1010...
...Sweden) owns 38% of Umecrine Mood. Umecrine Co. Group , Umea, Sweden Product: Sepranolone ( UC1010...
BioCentury | Jun 12, 2014
Clinical News

Umecrine's UC1010 misses in premenstrual dysphoric disorder

...The Umecrine Mood AB subsidiary of Umecrine Co. Group (Umea, Sweden) said subcutaneous UC1010 missed the...
...hoc analysis of patients with the "most severe problems" did show a significant difference between UC1010...
...patients. Umecrine Mood said it will further analyze the data before determining next steps for UC1010...
BioCentury | Jan 6, 2014
Clinical News

UC1010: Completed Phase I/II enrollment

...trial evaluating up to 40 mg/mL subcutaneous UC1010. The trial will evaluate single doses of UC1010...
...multiple doses in patients with premenstrual dysphoric disorder. Umecrine Co. Group , Umea, Sweden Product: UC1010...
BioCentury | Jun 10, 2013
Clinical News

UC1010: Phase I/II started

...40 mg/mL subcutaneous UC1010 in about 120 women. The trial will evaluate single doses of UC1010...
...multiple doses in patients with premenstrual dysphoric disorder. Umecrine Co. Group , Umea, Sweden Product: UC1010...
Items per page:
1 - 5 of 5